Lilly

Dicerna agrees another gene-silencing deal, this time with Lilly

https://pharmaphorum.com/news/dicerna-agrees-another-gene-silencing-deal-this-time-with-lilly/

Lilly looks to devices to revive diabetes division

https://pharmaphorum.com/news/lilly-dexcom-diabetes/

Lilly’s Verzenio fails in KRAS-mutated lung cancer

https://pharmaphorum.com/news/verzenio-fails-lung-cancer/

Lilly’s Verzenio joins breast cancer market

https://pharmaphorum.com/news/lillys-verzenio-joins-breast-cancer-market/

https://pharmaphorum.com/news/cymraza-help-bladder-cancer-patients-dont-respond-immunotherapy/

Diabetes drug Jardiance gains landmark cardiovascular approval

https://pharmaphorum.com/news/jardiancecvapproval/

Eye on ESMO: Day 2 – gamechangers take centre stage

https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/

New drugs boost Lilly in Q1 as company hopes for turnaround year

https://pharmaphorum.com/transversal-categories/sales-and-marketing/new-drugs-boost-lilly-as-company-hopes-for-turnaround-year/

Lilly pays AstraZeneca $100m as Alzheimer’s drug enters phase 3

https://pharmaphorum.com/news/lilly-pays-astrazeneca-100m-as-alzheimers-drug-enters-phase-3/

Close in 10 seconds

Pharmaphorum.com

Search